Gonadotropin-releasing hormone agonists and the risks of type 2 diabetes and cardiovascular disease in men with prostate cancer.

摘要

The adverse metabolic effects of androgen deprivation therapy (ADT) have only recently been described. In May 2010, the US FDA released a safety communication regarding gonadotropin-releasing hormone (GnRH) agonists and possible increased risk of type 2 diabetes and certain cardiovascular diseases (CVDs). In October 2010, the FDA then released a safety announcement requiring the manufacturers of GnRH agonists to add new information to the 'Warnings and Precautions' section of the drug labels.They specifically require warning of increased risk of diabetes and certain CVDs (heart attack, sudden cardiac death, stroke) in men receiving these medications for the treatment of prostate cancer.